Fusion protein having enhanced in vivo erythropoietin activity
Provided is a fusion protein comprising, at its carboxy terminal of human erythropoietin (EPO), a mutant having one to four amino acid substitutions in the carboxy terminal peptide (CTP) fragment of a human chorionic gonadotropin (HCG) subunit, for increasing an in vivo half-life activity of EPO. Th...
Saved in:
Main Authors | , , , , |
---|---|
Format | Patent |
Language | English |
Published |
19.06.2003
|
Online Access | Get full text |
Cover
Loading…
Summary: | Provided is a fusion protein comprising, at its carboxy terminal of human erythropoietin (EPO), a mutant having one to four amino acid substitutions in the carboxy terminal peptide (CTP) fragment of a human chorionic gonadotropin (HCG) subunit, for increasing an in vivo half-life activity of EPO. The in vivo half-life can be greatly elongated while retaining the intrinsic activity of the EPO, without increasing the sugar chain content. |
---|